CoChat

Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer

Open access

The DOI matches its Crossref record; 22 of the 23 references it cites were found in a registry or an index; 3 of the 33 sources its claims cite were checked for support.

Abstract

Background: The KRAS p.G12C mutation has recently become an actionable drug target. To further understand KRAS p.G12C disease, we describe clinicopathologic characteristics, treatment patterns, overall survival (OS), and real-world progression-free survival (rwPFS) in patients with metastatic colorectal cancer (mCRC), KRAS p.G12C mutations (KRAS G12C), and other KRAS mutations (KRAS non-G12C) using a de-identified database. Patients and Methods: Clinical and tumor characteristics, including treatments received, genomic profile, and clinical outcomes were assessed for patients from a US clinical genomic database with mCRC diagnosed between January 1, 2011, and March 31, 2020, with genomic sequencing data available. Results: Of 6477 patients with mCRC (mCRC cohort), 238 (3.7%) had KRAS G12C and 2947 (45.5%) had KRAS non-G12C mutations. Treatment patterns were generally comparable across lines of therapy (LOT) in KRAS G12C versus KRAS non-G12C cohorts. Median (95% CI) OS after the first LOT was 16.1 (13.0-19.0) months for the KRAS G12C cohort versus 18.3 (17.2-19.3) months for the KRAS non-G12C cohort, and 19.2 (18.5-19.8) months for the mCRC overall cohort; median (95% CI) rwPFS was 7.4 (6.3-9.5), 9.0 (8.2-9.7), and 9.2 (8.6-9.7) months, respectively. The different KRAS non-G12C mutations examined did not affect clinical outcomes. Median OS and rwPFS for all cohorts declined with each subsequent LOT. Conclusions: Patients with KRAS p.G12C-mutant mCRC have poor treatment outcomes, and outcomes appear numerically worse than for those without this mutation, indicating potential prognostic implications for KRAS p.G12C mutations and an unmet medical need in this population.

Overview

CoChat Summary

TL;DR

In a large US real-world clinical-genomic database, patients with KRAS p.G12C-mutant metastatic colorectal cancer had numerically shorter overall survival and real-world progression-free survival than patients with other KRAS mutations or the overall mCRC cohort. Treatment patterns were generally comparable across lines of therapy, suggesting potential prognostic implications and an unmet need for KRAS p.G12C-mutant mCRC.

Key findings

  • Among 6477 patients with mCRC, 238 (3.7%) had KRAS p.G12C and 2947 (45.5%) had KRAS non-G12C mutations.
  • After first-line therapy, median OS was 16.1 months (95% CI 13.0–19.0) for KRAS G12C, 18.3 months (17.2–19.3) for KRAS non-G12C, and 19.2 months (18.5–19.8) for the overall mCRC cohort; median rwPFS was 7.4 months (6.3–9.5), 9.0 months (8.2–9.7), and 9.2 months (8.6–9.7), respectively.
  • Median OS and rwPFS declined with each subsequent line of therapy in all cohorts; for KRAS G12C, median OS after first, second, third, and fourth LOT was 16.1, 9.7, 7.2, and 5.2 months, and median rwPFS was 7.4, 4.6, 2.1, and 3.0 months.
  • Treatment patterns were generally comparable across lines of therapy between KRAS G12C and KRAS non-G12C cohorts; the different KRAS non-G12C mutations examined did not appear to affect clinical outcomes.

Methods

  • Retrospective study of adults (≥18 years) with mCRC diagnosed between January 1, 2011, and March 31, 2020, using the US-based de-identified Flatiron Health–Foundation Medicine clinical-genomic database, with follow-up through September 2020.
  • Patients were assigned to KRAS p.G12C, KRAS non-G12C, RAS/BRAF wild-type, overall mCRC, and selected subgroup cohorts (BRAF V600E, KRAS G12D, G12V, G13D) based on comprehensive genomic profiling of >300 cancer-related genes.
  • Analyses were descriptive with no formal hypothesis testing; OS and rwPFS were estimated by Kaplan-Meier methods, with delayed-entry statistics used to address immortal time bias.

Limitations

  • The authors state that median age was 60 years, slightly younger than reported elsewhere (~65 years), and the percentage of Black patients was lower than expected; the database also lacks information such as the proportion of patients who had metastasectomy.
  • The authors state that results may not be generalizable to patients outside the US, treated at academic centers, or who did not undergo genomic sequencing or were sequenced by different methodologies; rwPFS differs from clinical trial PFS and may not be comparable to trial outcomes.
  • Evident from the text: analyses were descriptive without formal hypothesis testing, no missing data were imputed, and rwPFS relied on physician evaluation abstracted from EHRs, likely based on less frequent and less systematic assessments than RECIST in clinical trials.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1093/oncolo/oyac077

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. Treatment Patterns During (A) First, (B) Second, (C) Third, and (D) Fourth Lines of Therapy. BRAF, B-Raf proto oncogene; FU, fluorouracil; KRAS, Kirsten rat sarcoma viral oncogene homolog; KRAS G12C, KRAS p.G12C-mutant mCRC cohort; KRAS non-G12C, mCRC cohort including KRAS mutants other than KRAS p.G12C; mCRC, metastatic colorectal cancer; RAS, rat sarcoma viral oncogene homolog; WT, wild-type. aAntiangiogenic agents described here are either bevacizumab, ramucirumab, and/or ziv-aflibercept. b“Other” includes oxaliplatin and fluoropyrimidine and (cetuximab or panitumumab); irinotecan and fluoropyrimidine and (cetuximab or panitumumab); irinotecan and oxaliplatin +/− antiangiogenic agent; irinotecan monotherapy +/− antiangiogenic agent; irinotecan monotherapy and (cetuximab or panitumumab); oxaliplatin and irinotecan and fluoropyrimidine +/− antiangiogenic agent; trifluridine and tipiracil; regorafenib monotherapy; immune checkpoint inhibitor(s).
Figure 1. Treatment Patterns During (A) First, (B) Second, (C) Third, and (D) Fourth Lines of Therapy. BRAF, B-Raf proto oncogene; FU, fluorouracil; KRAS, Kirsten rat sarcoma viral oncogene homolog; KRAS G12C, KRAS p.G12C-mutant mCRC cohort; KRAS non-G12C, mCRC cohort including KRAS mutants other than KRAS p.G12C; mCRC, metastatic colorectal cancer; RAS, rat sarcoma viral oncogene homolog; WT, wild-type. aAntiangiogenic agents described here are either bevacizumab, ramucirumab, and/or ziv-aflibercept. b“Other” includes oxaliplatin and fluoropyrimidine and (cetuximab or panitumumab); irinotecan and fluoropyrimidine and (cetuximab or panitumumab); irinotecan and oxaliplatin +/− antiangiogenic agent; irinotecan monotherapy +/− antiangiogenic agent; irinotecan monotherapy and (cetuximab or panitumumab); oxaliplatin and irinotecan and fluoropyrimidine +/− antiangiogenic agent; trifluridine and tipiracil; regorafenib monotherapy; immune checkpoint inhibitor(s).CC BY-NC · PubMed Central
Figure 2. Median (A) OS and (B) rwPFS among patients in the KRAS G12C, KRAS non-G12C (including major subgroups), and overall mCRC (including the RAS/BRAF WT and BRAF V600E mutant subgroups) cohorts in first-line and second-line settings. BRAF, B-Raf proto oncogene; KRAS, Kirsten rat sarcoma viral oncogene homolog; KRAS G12C, KRAS p.G12C-mutant mCRC cohort; KRAS G12D, KRAS p.G12D-mutant mCRC subgroup; KRAS G12V, KRAS p.G12V-mutant mCRC subgroup; KRAS G13C, KRAS p.G13C-mutant mCRC subgroup; KRAS non-G12C, mCRC cohort including KRAS mutants other than KRAS p.G12C; mCRC, metastatic colorectal cancer; OS, overall survival; RAS, rat sarcoma viral oncogene homolog; rwPFS, real-world progression-free survival; WT, wild-type.
Figure 2. Median (A) OS and (B) rwPFS among patients in the KRAS G12C, KRAS non-G12C (including major subgroups), and overall mCRC (including the RAS/BRAF WT and BRAF V600E mutant subgroups) cohorts in first-line and second-line settings. BRAF, B-Raf proto oncogene; KRAS, Kirsten rat sarcoma viral oncogene homolog; KRAS G12C, KRAS p.G12C-mutant mCRC cohort; KRAS G12D, KRAS p.G12D-mutant mCRC subgroup; KRAS G12V, KRAS p.G12V-mutant mCRC subgroup; KRAS G13C, KRAS p.G13C-mutant mCRC subgroup; KRAS non-G12C, mCRC cohort including KRAS mutants other than KRAS p.G12C; mCRC, metastatic colorectal cancer; OS, overall survival; RAS, rat sarcoma viral oncogene homolog; rwPFS, real-world progression-free survival; WT, wild-type.CC BY-NC · PubMed Central
Figure 3. Overall survival (OSa) and real-world progression-free survival (rwPFS) in first-line and second-line settings. aOS is measured from the start of the line of therapy to death or censored at last activity date in the FH/FMI networks. 95% CIs are based on estimated variance for log-log transformation of the Kaplan-Meier survival estimate. BRAF, B-Raf proto oncogene; FH, Flatiron Health; FMI, Foundation Medicine; KRAS, Kirsten rat sarcoma viral oncogene homolog; KRAS G12C, KRAS p.G12C-mutant mCRC cohort; KRAS non-G12C, mCRC cohort including KRAS mutants other than KRAS p.G12C; mCRC, metastatic colorectal cancer; OS, overall survival; RAS, rat sarcoma viral oncogene homolog; rwPFS, real-world progression-free survival; WT, wild-type.
Figure 3. Overall survival (OSa) and real-world progression-free survival (rwPFS) in first-line and second-line settings. aOS is measured from the start of the line of therapy to death or censored at last activity date in the FH/FMI networks. 95% CIs are based on estimated variance for log-log transformation of the Kaplan-Meier survival estimate. BRAF, B-Raf proto oncogene; FH, Flatiron Health; FMI, Foundation Medicine; KRAS, Kirsten rat sarcoma viral oncogene homolog; KRAS G12C, KRAS p.G12C-mutant mCRC cohort; KRAS non-G12C, mCRC cohort including KRAS mutants other than KRAS p.G12C; mCRC, metastatic colorectal cancer; OS, overall survival; RAS, rat sarcoma viral oncogene homolog; rwPFS, real-world progression-free survival; WT, wild-type.CC BY-NC · PubMed Central
Figure 4. Median OS after first-line treatment among subgroups in the (A) KRAS G12C, (B) KRAS Non-G12C Cohorts. - - - - Indicates overall median OS for first line of treatment. a1L regimen only includes the listed chemotherapy doublets; other regimens (eg, chemotherapy triples or chemotherapy doubles with anti-EGFR) are not included. 1L, first line of treatment; BRAF, B-Raf proto oncogene; Dx, diagnosis; KRAS, Kirsten rat sarcoma viral oncogene homolog; KRAS G12C, KRAS p.G12C-mutant mCRC cohort; KRAS non-G12C, mCRC cohort including KRAS mutants other than KRAS p.G12C; mCRC, metastatic colorectal cancer; OS, overall survival; RAS, rat sarcoma viral oncogene homolog; RAS/BRAF WT, RAS/BRAF WT mCRC cohort; WT, wild-type.
Figure 4. Median OS after first-line treatment among subgroups in the (A) KRAS G12C, (B) KRAS Non-G12C Cohorts. - - - - Indicates overall median OS for first line of treatment. a1L regimen only includes the listed chemotherapy doublets; other regimens (eg, chemotherapy triples or chemotherapy doubles with anti-EGFR) are not included. 1L, first line of treatment; BRAF, B-Raf proto oncogene; Dx, diagnosis; KRAS, Kirsten rat sarcoma viral oncogene homolog; KRAS G12C, KRAS p.G12C-mutant mCRC cohort; KRAS non-G12C, mCRC cohort including KRAS mutants other than KRAS p.G12C; mCRC, metastatic colorectal cancer; OS, overall survival; RAS, rat sarcoma viral oncogene homolog; RAS/BRAF WT, RAS/BRAF WT mCRC cohort; WT, wild-type.CC BY-NC · PubMed Central
Figure 5. Median OS after first-line treatment among subgroups in the (A) RAS/BRAF WT and (B) Overall mCRC Cohorts. - - - - Indicates overall median OS for first line of treatment. a1L regimen only includes the listed chemotherapy doublets; other regimens (eg, chemotherapy triples or chemotherapy doubles with anti-EGFR) are not included. 1L, first line of treatment; BRAF, B-Raf proto oncogene; Dx, diagnosis; KRAS, Kirsten rat sarcoma viral oncogene homolog; KRAS G12C, KRAS p.G12C-mutant mCRC cohort; KRAS non-G12C, mCRC cohort including KRAS mutants other than KRAS p.G12C; mCRC, metastatic colorectal cancer; OS, overall survival; RAS, rat sarcoma viral oncogene homolog; RAS/BRAF WT, RAS/BRAF WT mCRC cohort; WT, wild-type.
Figure 5. Median OS after first-line treatment among subgroups in the (A) RAS/BRAF WT and (B) Overall mCRC Cohorts. - - - - Indicates overall median OS for first line of treatment. a1L regimen only includes the listed chemotherapy doublets; other regimens (eg, chemotherapy triples or chemotherapy doubles with anti-EGFR) are not included. 1L, first line of treatment; BRAF, B-Raf proto oncogene; Dx, diagnosis; KRAS, Kirsten rat sarcoma viral oncogene homolog; KRAS G12C, KRAS p.G12C-mutant mCRC cohort; KRAS non-G12C, mCRC cohort including KRAS mutants other than KRAS p.G12C; mCRC, metastatic colorectal cancer; OS, overall survival; RAS, rat sarcoma viral oncogene homolog; RAS/BRAF WT, RAS/BRAF WT mCRC cohort; WT, wild-type.CC BY-NC · PubMed Central
Figure 6. Median rwPFS after first-line treatment among subgroups in the (A) KRAS G12C, (B) KRAS Non-G12C cohorts. - - - - Indicates overall median rwPFS for first line of treatment. a1L regimen only includes the listed chemotherapy doublets; other regimens (eg, chemotherapy triples or chemotherapy doubles with anti-EGFR) are not included. 1L, first line of treatment; BRAF, B-Raf proto oncogene; Dx, diagnosis; KRAS, Kirsten rat sarcoma viral oncogene homolog; KRAS G12C, KRAS p.G12C-mutant mCRC cohort; KRAS non-G12C, mCRC cohort including KRAS mutants other than KRAS p.G12C; mCRC, metastatic colorectal cancer; RAS, rat sarcoma viral oncogene homolog; RAS/BRAF WT, RAS/BRAF WT mCRC cohort; rwPFS, real-world progression-free survival; WT, wild-type.
Figure 6. Median rwPFS after first-line treatment among subgroups in the (A) KRAS G12C, (B) KRAS Non-G12C cohorts. - - - - Indicates overall median rwPFS for first line of treatment. a1L regimen only includes the listed chemotherapy doublets; other regimens (eg, chemotherapy triples or chemotherapy doubles with anti-EGFR) are not included. 1L, first line of treatment; BRAF, B-Raf proto oncogene; Dx, diagnosis; KRAS, Kirsten rat sarcoma viral oncogene homolog; KRAS G12C, KRAS p.G12C-mutant mCRC cohort; KRAS non-G12C, mCRC cohort including KRAS mutants other than KRAS p.G12C; mCRC, metastatic colorectal cancer; RAS, rat sarcoma viral oncogene homolog; RAS/BRAF WT, RAS/BRAF WT mCRC cohort; rwPFS, real-world progression-free survival; WT, wild-type.CC BY-NC · PubMed Central
Figure 7. Median rwPFS after first-line treatment among subgroups in the (A) RAS/BRAF WT, and (B) overall mCRC cohorts. - - - - Indicates overall median rwPFS for first line of treatment. a1L regimen only includes the listed chemotherapy doublets; other regimens (eg, chemotherapy triples or chemotherapy doubles with anti-EGFR) are not included. 1L, first line of treatment; BRAF, B-Raf proto oncogene; Dx, diagnosis; KRAS, Kirsten rat sarcoma viral oncogene homolog; KRAS G12C, KRAS p.G12C-mutant mCRC cohort; KRAS non-G12C, mCRC cohort including KRAS mutants other than KRAS p.G12C; mCRC, metastatic colorectal cancer; RAS, rat sarcoma viral oncogene homolog; RAS/BRAF WT, RAS/BRAF WT mCRC cohort; rwPFS, real-world progression-free survival; WT, wild-type.
Figure 7. Median rwPFS after first-line treatment among subgroups in the (A) RAS/BRAF WT, and (B) overall mCRC cohorts. - - - - Indicates overall median rwPFS for first line of treatment. a1L regimen only includes the listed chemotherapy doublets; other regimens (eg, chemotherapy triples or chemotherapy doubles with anti-EGFR) are not included. 1L, first line of treatment; BRAF, B-Raf proto oncogene; Dx, diagnosis; KRAS, Kirsten rat sarcoma viral oncogene homolog; KRAS G12C, KRAS p.G12C-mutant mCRC cohort; KRAS non-G12C, mCRC cohort including KRAS mutants other than KRAS p.G12C; mCRC, metastatic colorectal cancer; RAS, rat sarcoma viral oncogene homolog; RAS/BRAF WT, RAS/BRAF WT mCRC cohort; rwPFS, real-world progression-free survival; WT, wild-type.CC BY-NC · PubMed Central

Verification

Claims the paper makes

1 Valid · 0 Not valid · 20 Not checked · 46 Own results and interpretations

21 more claims

Create a free account to see all 67 claims and to verify the 30 references still open.

See all claims — free account
  • It may state two separate claims as one. 36
  • Probably not a substantial claim. 9

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

1 of 1

Citations

Cites

Show all 22 references

Research works printed but not linked: 1

  1. American Cancer Society., 2019, Cancer Facts & Figures for African Americans 2019-2021

Cited by

Metadata

Authors
Fakih, M., Tu, H., Hsu, H., Aggarwal, S., Chan, E., Rehn, M., Chia, V., & Kopetz, S.
Affiliations
  • City Of Hope National Medical Center (US)
  • Amgen (United States) (US)
  • The University of Texas MD Anderson Cancer Center (US)
Corresponding author
  • Fakih, Marwan
  • Tu, Huakang
  • Aggarwal, Shivani
Venue
The Oncologist
Published
2022-04-26
Volume
27
Issue
8
Pages
663-674
ISSN
  • 1083-7159 (ISSN-L)
  • 1549-490X
OpenAlex
W4224981845
Cited by
43
References
23
Citations by year
2026: 8 · 2025: 8 · 2024: 14 · 2023: 8 · 2022: 5
FWCI
3.66
Type
journal article
Language
en
Open access
Locations
  • The Oncologist (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
Amgen Inc
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Keywords
metastatic colorectal cancer, overall survival, progression-free survival, treatment patterns, treatment lines, clinicopathological features, prognostic implications, KRAS inhibitors
MeSH terms
Colonic Neoplasms, Humans, Mutation, Prognosis, Rectal Neoplasms, Colorectal Neoplasms, Proto-Oncogene Proteins p21(ras), Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-11-20, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-11-20 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.